Literature DB >> 19427513

Centrosomal amplification and aneuploidy induced by the antiretroviral drug AZT in hamster and human cells.

Jennifer P Borojerdi1, Jessica Ming, Catherine Cooch, Yvona Ward, Cristina Semino-Mora, Mia Yu, Hannan M Braun, Barbara J Taylor, Miriam C Poirier, Ofelia A Olivero.   

Abstract

The centrosome directs chromosomal migration by a complex process of tubulin-chromatin binding. In this contribution centrosomal abnormalities, including centrosomal amplification, were explored in Chinese hamster ovary (CHO) and normal human mammary epithelial cells (NHMECs) exposed to the antiretroviral drug zidovudine (3'-azido-3'-deoxythymidine, AZT). Centrosomal amplification/fragmentation was observed in both cell types and kinetochore positive micronuclei were found in AZT-exposed CHO cells in correlation with dose. Normal human mammary epithelial cell (NMHEC) strain M99005, previously identified as a strain that incorporates high levels of AZT into DNA (high incorporator, HI), showed greater centrosomal amplification when compared with a second strain, NHMEC M98040, which did not incorporate AZT into DNA (low incorporator, LI). Additionally, an abnormal tubulin distribution was observed in AZT-exposed HI cells bearing multiple centrosomes. Immunofluorescent staining of human cells with Aurora A, a kinase involved in the maturation of the centrosome, confirmed the induction of centrosomal amplification and revealed multipolar mitotic figures. Flow cytometric studies revealed that cells bearing abnormal numbers of centrosomes and abnormal tubulin distribution had similar S-phase percentages suggesting that cells bearing unbalanced chromosomal segregation could divide. Therefore, AZT induces genomic instability and clastogenicity as well as alterations in proteins involved in centrosomal activation, all of which may contribute to the carcinogenic properties of this compound.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427513      PMCID: PMC2680773          DOI: 10.1016/j.mrfmmm.2009.03.004

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  27 in total

1.  Requirement of a centrosomal activity for cell cycle progression through G1 into S phase.

Authors:  E H Hinchcliffe; F J Miller; M Cham; A Khodjakov; G Sluder
Journal:  Science       Date:  2001-02-23       Impact factor: 47.728

Review 2.  Centrosome amplification and the development of cancer.

Authors:  Antonino B D'Assoro; Wilma L Lingle; Jeffrey L Salisbury
Journal:  Oncogene       Date:  2002-09-09       Impact factor: 9.867

Review 3.  The survivin/Aurora B complex: its role in coordinating tension and attachment.

Authors:  Susanne M A Lens; René H Medema
Journal:  Cell Cycle       Date:  2003 Nov-Dec       Impact factor: 4.534

Review 4.  Cell death by mitotic catastrophe: a molecular definition.

Authors:  Maria Castedo; Jean-Luc Perfettini; Thomas Roumier; Karine Andreau; Rene Medema; Guido Kroemer
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

5.  The detertent-resistant cytoskeleton of tissue culture cells includes the nucleus and the microfilament bundles.

Authors:  M Osborn; K Weber
Journal:  Exp Cell Res       Date:  1977-05       Impact factor: 3.905

Review 6.  Enzymatic repair of oxidative DNA damage.

Authors:  M S Satoh; T Lindahl
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

7.  Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice.

Authors:  B A Diwan; C W Riggs; D Logsdon; D C Haines; O A Olivero; J M Rice; S H Yuspa; M C Poirier; L M Anderson
Journal:  Toxicol Appl Pharmacol       Date:  1999-11-15       Impact factor: 4.219

8.  Human inter-individual variability in metabolism and genotoxic response to zidovudine.

Authors:  Ofelia A Olivero; Jessica M Ming; Shreyasi Das; Irma L Vazquez; Diana L Richardson; Ainsley Weston; Miriam C Poirier
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-14       Impact factor: 4.219

9.  Arrest of cell cycle progression during first interphase in murine zygotes microinjected with anti-PCM-1 antibodies.

Authors:  R Balczon; C Simerly; D Takahashi; G Schatten
Journal:  Cell Motil Cytoskeleton       Date:  2002-07

10.  Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro.

Authors:  M C Semino-Mora; M E Leon-Monzon; M C Dalakas
Journal:  Lab Invest       Date:  1994-07       Impact factor: 5.662

View more
  12 in total

1.  Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosine.

Authors:  Mia Yu; Yvona Ward; Miriam C Poirier; Ofelia A Olivero
Journal:  Environ Mol Mutagen       Date:  2009-10       Impact factor: 3.216

Review 2.  Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancy.

Authors:  Miriam C Poirier; Alexander T Gibbons; Maria T Rugeles; Isabelle Andre-Schmutz; Stephane Blanche
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

3.  Nuclear bud formation: a novel manifestation of Zidovudine genotoxicity.

Authors:  A Dutra; E Pak; S Wincovitch; K John; M C Poirier; O A Olivero
Journal:  Cytogenet Genome Res       Date:  2010-04-20       Impact factor: 1.636

4.  Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine.

Authors:  Jia-Long Fang; Tao Han; Qiangen Wu; Frederick A Beland; Ching-Wei Chang; Lei Guo; James C Fuscoe
Journal:  Arch Toxicol       Date:  2013-11-30       Impact factor: 5.153

5.  Perinatal exposure of patas monkeys to antiretroviral nucleoside reverse-transcriptase inhibitors induces genotoxicity persistent for up to 3 years of age.

Authors:  Ofelia A Olivero; Lorangelly Rivera Torres; Sayeh Gorjifard; Dariya Momot; Eryney Marrogi; Rao L Divi; Yongmin Liu; Ruth A Woodward; Marsha J Sowers; Miriam C Poirier
Journal:  J Infect Dis       Date:  2013-04-04       Impact factor: 5.226

6.  Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes.

Authors:  Jia-Long Fang; Frederick A Beland
Journal:  Toxicol Sci       Date:  2009-06-18       Impact factor: 4.849

7.  Selective protection of zidovudine-induced DNA-damage by the antioxidants WR-1065 and tempol.

Authors:  Ofelia A Olivero; Michael O Ongele; Hannan M Braun; Ariadna Marrogi; Kathyiani Divi; James B Mitchell; Miriam C Poirier
Journal:  Environ Mol Mutagen       Date:  2014-05-16       Impact factor: 3.216

8.  Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Authors:  Christina N Bennett; Christine C Tomlinson; Aleksandra M Michalowski; Isabel M Chu; Dror Luger; Lara R Mittereder; Olga Aprelikova; James Shou; Helen Piwinica-Worms; Natasha J Caplen; Melinda G Hollingshead; Jeffrey E Green
Journal:  Breast Cancer Res       Date:  2012-07-19       Impact factor: 6.466

9.  Role of DNA Repair Pathways in Response to Zidovudine-induced DNA Damage in Immortalized Human Liver THLE2 Cells.

Authors:  Qiangen Wu; Frederick A Beland; Ching-Wei Chang; Jia-Long Fang
Journal:  Int J Biomed Sci       Date:  2013-03

10.  Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data.

Authors:  Luiz Euribel Prestes-Carneiro
Journal:  HIV AIDS (Auckl)       Date:  2013-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.